Open-label surgical trials for Parkinson disease: Time for reconsideration

Annals of Neurology

Volumn 70, Issue 1, 2011, Pages 5-8

  Alterman, Ron L ^a   Tagliati, Michele ^b   Olanow, C Warren ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEURTURIN; PLACEBO;

ARTICLE; BIOLOGICAL THERAPY; BRAIN DEPTH STIMULATION; BRAIN INFARCTION; BRAIN TOXICITY; BRAIN TRANSPLANTATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; MESENCEPHALIC TRIGEMINAL NUCLEUS; MESENCEPHALON; NEUROSURGERY; NONHUMAN; OPEN STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHAM PROCEDURE; UNIFIED PARKINSON DISEASE RATING SCALE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE; TIME FACTORS;

EID: 79960799815     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22453     Document Type: Article

References (27)

1. Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. New Engl J Med 1992; 327: 1549-1555.
2. Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson's disease. Arch Neurol 1999; 56: 179-187. (Pubitemid 29076182)
3. Schumacher JM, Ellias SA, Palmer EP, et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 2000; 54: 1042-1050. (Pubitemid 30151843)
4. Patel NK, Bunnage M, Plaha P, et al. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 2005; 57: 298-302. (Pubitemid 40179870)
5. Slevin JT, Gash DM, Smith CD, et al. Unilateral intraputaminal glial cell-line derived neurotrophic factor in patients with Parkinson's disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 2007; 106: 614-620. (Pubitemid 46536457)
6. Stover NP, Bakay RAE, Subramanian T, et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson's disease. Arch Neurol 2005; 62: 1833-1837. (Pubitemid 41785076)
7. Marks WJ, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008; 7: 400-408.
8. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-719. (Pubitemid 32204988)
9. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-414. (Pubitemid 37072046)
10. GenVec. Genzyme and Diacrin report preliminary results from phase 2 trial of NeuroCell(TM)-PD. Available at:. Accessed on January 14, 2010.
11. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputaminal glial cell line-derived neurotrophic factor infusion in Parkinson's disease. Ann Neurol 2006; 59: 459-466. (Pubitemid 43358066)
12. Titan Pharmaceuticals announces Spheramine initial phase IIb results. Available at:. Accessed on January 14, 2010.
13. Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9: 1142-1143.
14. Freeman TB, Vawter DE, Leaverton PE, et al. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med 1999; 341: 988-992. (Pubitemid 29441556)
15. Macklin R,. The ethical problems with sham surgery in clinical research. N Engl J Med 1999; 341: 992-996.
16. Dekkers W, Boer G,. Sham neurosurgery in patients with Parkinson's disease: is it morally acceptable? J Med Ethics 2001; 27: 151-156. (Pubitemid 32982844)
17. Kim SYH, Frank S, Holloway R, et al. Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers. Arch Neurol 2005; 62: 1357-1360. (Pubitemid 41352051)
18. Olanow CW,. Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease. Arch Neurol 2005; 62: 1343-1344. (Pubitemid 41352049)
19. Goetz CG, Wuu J, McDermott MP, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008; 23: 690-699.
20. Kaptchuk TJ, Stason WB, Davis RB, et al. Sham device v. inert pill: randomized controlled trial of two placebo treatments. BMJ 2006; 332: 391-397.
21. de la Fuente-Fernández R, Ruth TJ, Sossi V, et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-1166. (Pubitemid 32758101)
22. Pollo A, Benedetti F,. The placebo response: neurobiological and clinical issues of neurological relevance. Prog Brain Res 2009; 175: 283-294.
23. Zubieta JK, Stohler CS,. Neurobiological mechanisms of placebo response. Ann N Y Acad Sci; 2009; 1156: 198-210.
24. Frank S, Kieburtz K, Holloway R, Kim SY,. What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports. Neurology 2005; 65: 1101-1103. (Pubitemid 41429639)
25. Frank SA, Wilson R, Holloway RG, et al. Ethics of sham surgery: perspective of patients. Mov Disord 2008; 23: 63-68. (Pubitemid 351281219)
26. Olanow CW, Gracies J-M, Goetz CC, et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double-blind video-based analysis. Mov Disord 2009; 24: 336-343.
27. Patel NK, Gill SS,. GDNF delivery for Parkinson's disease. Acta Neurochir Suppl 2007; 97 (pt 2): 135-154.